c-MET as a Potential Therapeutic Target in Ovarian Clear Cell Carcinoma

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• Ovarian clear cell carcinoma (OCCC) is a subtype of epithelial ovarian cancer (EOC) with distinct characteristics.
• The c-MET signaling pathway is implicated in various cancers, suggesting its potential role in OCCC pathogenesis.
• Understanding the therapeutic potential of targeting c-MET in OCCC is crucial for developing novel treatment strategies.

Purpose of the Study:

• To investigate the therapeutic effects of c-MET inhibition in ovarian clear cell carcinoma (OCCC).
• To evaluate c-MET expression levels in OCCC tissues compared to other ovarian cancer subtypes and normal tissues.
• To assess the impact of c-MET inhibitors on OCCC cell proliferation, apoptosis, and tumor growth in preclinical models.

Main Methods:

• Real-time PCR was used to quantify c-MET expression in tumor samples and normal tissues.
• In vitro assays (MTT, apoptosis) were performed using OCCC cell lines treated with c-MET inhibitors (SU11274, crizotinib).
• Western blotting assessed c-MET pathway activation, and in vivo studies utilized orthotopic mouse xenografts and patient-derived xenografts (PDX) to evaluate tumor growth inhibition.

Main Results:

• c-MET expression was significantly elevated in OCCC compared to serous carcinomas and normal ovarian tissues (p < 0.001).
• In vitro, c-MET inhibitors markedly reduced OCCC cell proliferation and induced apoptosis.
• SU11274 treatment inhibited the c-MET pathway, decreasing p-c-MET, Akt, and Erk phosphorylation, and significantly reduced tumor weight in both cell line and PDX xenograft models (p = 0.004 and p = 0.009, respectively).

Conclusions:

• c-MET is overexpressed in OCCC and represents a viable therapeutic target.
• Inhibition of c-MET demonstrates significant anti-tumor activity in both in vitro and in vivo models of OCCC.
• Targeting the c-MET pathway holds promise for the development of novel therapeutic strategies for ovarian clear cell carcinoma.